| Wenqing Wei. Clinical predictive values of biomarker levels in non-small cell lung cancer. Oncol Transl Med, 2017, 3: 245-248. |
| 非小细胞肺癌患者血清生物标记物水平变化及临床意义 |
| Clinical predictive values of biomarker levels in non-small cell lung cancer |
| Received:July 18, 2017 Revised:January 21, 2018 |
| DOI：10.1007/s10330-017-0236-6 |
| 中文关键词: 非小细胞肺癌；程序性死亡受体1（PD-1）；IL-17；IL-21 |
| 英文关键词: non-small cell lung cancer; PD-1; IL-17; IL-21 |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Wenqing Wei* | Army General Hospital, Beijing, 100700, China | wqwei2000@qq.com |
|
| Hits: 9998 |
| Download times: 11079 |
| 中文摘要: |
| 摘要：目的 本研究分析了非小细胞肺癌（NSCLC）患者术前术后血清程序性死亡受体1（programmed cell death protein 1,PD-1）、IL-17及IL-21的水平变化，旨在探讨PD-1、IL-17及IL-21水平在NSCLC病程发展及预后中的临床意义。方法 采用酶联免疫分析法测定了45名NSCLC患者术前、术后的血清PD-1、IL-17及IL-21含量，分析了不同病程患者血清PD-1、IL-17及IL-21水平。随机选择30名健康志愿者血清PD-1、IL-17及IL-21水平作为对照组。结果 术前组和对照组之间血清PD-1、IL-17及IL-21水平具有显著差异（P＜0.01），术后组和对照组之间血清IL-17、IL-21水平无显著差异（P＞0.05）；术前组与术后组比较，血清PD-1、IL-17水平明显降低（P＜0.01），血清IL-21水平明显升高（P＜0.05）。晚期肺癌患者血清PD-1、IL-17水平高于早期肺癌患者（P＜0.05），而IL-21水平则低于早期肺癌患者（P＜0.05）。结论 NSCLC患者血清中PD-1、IL-17、IL-21水平变化与手术、NSCLC病程相关，监测PD-1、IL-17、IL-21水平对NSCLC的治疗和预后有一定的指导意义。 |
| 英文摘要: |
| Objective To evaluate the predictive value of serum levels of PD-1, IL-17, and IL-21 in patients with nonsmall
cell lung cancer.
Methods Serum levels of PD-1, IL-17, and IL-21 were analyzed by ELISA in 45 patients with non-small
cell lung cancer (NSCLC) and 30 healthy individuals.
Results Serum PD-1, IL-17, and IL-21 levels were significantly different between preoperative patients
with NSCLC and the control group (P < 0.01), while there was no significant differences between the
postoperative patients and the control group (P > 0.05). Comparison of serum PD-1, IL-17, and IL-21 levels
of patients with NSCLC before and after the operation revealed a decrease in PD-1 and IL-17 levels and an
increase in IL-21 levels. The serum levels of PD-1 and IL-17 were higher in patients with advanced staged
disease than in those with early stage cancer (P < 0.05), while IL-21 levels were lower at the advanced
stages (P < 0.05).
Conclusion In patients with NSCLC, serum levels of PD-1, IL-17, and IL-21 changed considering the
surgical operation and the course of the disease. Screening these biomarker levels might provide a helpful
index for treatment and prognosis. |
|
View Full Text
Download reader HTML全文 |
| Close |